Skip to content

Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)

Efficacy and Safety of Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03758196
Enrollment
126
Registered
2018-11-29
Start date
2018-10-31
Completion date
2021-12-31
Last updated
2020-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant Hypertension

Keywords

renal sympathetic denervation, resistant hypertension

Brief summary

As one of the most common chronic diseases,The adult prevalence of hypertension is approximately 26.4% at present and will rise to 29.2% by 2025.Renal sympathetic denervation from the intima of renal artery has emerged as a potential treatment for resistant hypertension. However, renal sympathetic nerve are mainly located in the adventitia,and there is no report on renal sympathetic denervation from the adventitia of renal artery.This study is a multicenter,randomized,single-blind study,and aimed to observe the safety and efficacy of radiofrequency ablation of the renal artery from the adventitia on the basis of laparoscopic techniques for patients with resistant hypertension.

Detailed description

This study is a multicenter,randomized,single-blind study,and aimed to observe the safety and efficacy of radiofrequency ablation of the renal artery from the adventitia on the basis of laparoscopic techniques for patients with resistant hypertension.

Interventions

DEVICERadiofrequency ablation instruments

Renal Sympathetic Denervation from the adventitia of renal artery

Sponsors

Henan Institute of Cardiovascular Epidemiology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1.18 years old ≤ age ≤ 65 years old; 2.Patients with clear diagnosis of resistant hypertension prior to enrollment:On the basis of improving lifestyle, a reasonable and tolerable amount of 3 or more kinds of antihypertensive drugs (including diuretics) for more than one month, clinic SBP≥140mmHg or (and) DBP≥90mmHg, 24 hours dynamic Blood pressure monitoring SBP\>130mmHg or (and) DBP\>80mmHg; 3.Estimated GFR (eGFR) ≥ 60ml/min/1.73m2; 4.The patient or his legal guardian has signed the informed consent; 5.Patients who are willing and able to perform follow-up visits.

Exclusion criteria

1. Patients with secondary hypertension caused by any known cause; 2. pregnant or planning to be pregnant; 3. Patients with renal artery diameter \<4mm or length \<20mm; 4. Patients with renal artery abnormalities include: hemodynamic or anatomically significant stenosis (≥50%) of renal arteries on either side;renal arterial balloon angioplasty or stenting;renal involvement on either side Multiple renal arteries,and renal arteries supply \<75% of the kidneys;abnormal renal artery anatomy,such as tumor expansion; 5. Patients with cardiovascular instability factors includes:acute myocardial infarction within six months,unstable angina or cerebrovascular disease;heart valve disease with significantly altered hemodynamics; 6. Patients with other serious organic diseases; 7. Patients participated in other studies.

Design outcomes

Primary

MeasureTime frame
Change in 24-hour average systolic blood pressure by ABPM in 6 months after discharge .Baseline to 6 months

Secondary

MeasureTime frame
Change in 24-hour average diastolic blood pressure,daytime and nighttime systolic/diastolic blood pressure by ABPM in 6 months after dischargeBaseline to 6 months
Change in 24-hour average blood pressure,daytime and nighttime systolic/diastolic blood pressure by ABPM in 1,3,12 months after dischargeBaseline to 1 months,3 months,12 months
Change in office systolic/diastolic blood pressure in 1,3,6,12 months after dischargeBaseline to 1 months,3 months,6 months,12 months
Change in types and doses of antihypertensive medications in 1,3,6,12 months after discharge.Baseline to 1 months,3 months,6 months,12 months
renal function in 1,3,6,12 months after dischargeBaseline to 1 months,3 months,6 months,12 months
The surgical complications of renal artery perforation,such as stenosis,and dissection associated with radiofrequency surgery.And major cardiovascular and cerebrovascular events ,including cardiac death,stroke and nonfatal- myocardial infarction.Baseline to 6 months,12 months
Change in systolic/diastolic blood pressure by home blood pressure monitoring in 1,3,6,12 months after dischargeBaseline to 1 months,3 months,6 months,12 months

Countries

China

Contacts

Primary ContactYahui Liu, Bachelor
1182600873@qq.com+86 18317898825
Backup ContactChuanyu Gao, Dr.
gaocy6802@163.com+86 13937165590

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026